Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy (NICEFIT ON)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/37650
• EU PAS number:
  EUPAS37649
• Study ID:
  37650
• Official title and acronym:
  Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy (NICEFIT ON)
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  The primary objective is to characterize the long-term treatment outcome of nintedanib for IPF/SSc-ILD/PF-ILD population regarding the disease course under the clinical practice in Taiwan. The secondary objective is to discover diagnostic/prognostic factors for patients with IPF/SSc-ILD/PF-ILD.
• Study status:
  Planned

Research institutions and networks

Institutions

National Taiwan University Hospital (NTUH)

Study timelines

Date when funding contract was signed

Planned: 01/06/2019

Actual: 30/06/2016

Study start date

Planned: 03/11/2020

Date of final study report

Planned: 31/12/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable